ClinicalTrials.gov
public full text
Public Domain
Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
This study will evaluate the safety, tolerability and exposure of SB-751689 when administered alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a PGP/CYP3A4 inhibitor that increases exposure of SB-751689. Data from this study will enable the planning and conduct of a QTc study for SB-751689.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects#1140245
- A First-in-Human Study of LY3009385 in Healthy Participants#837388
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo#806293
- A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017#1153817
- Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816#1086441
Record · ID 1058728
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive